Engineering immunotherapeutic probiotics to mitigate irAE
Description: PROJECT NARRATIVE Cancer immunotherapies have demonstrated significant clinical success for subgroups of patients with varying malignancies. However, due in part to their systemic administration, therapeutic limitations include immune- related adverse effects and diminished efficacy due to poor tumor penetration. This proposal seeks to engineer immunotherapeutic probiotic bacteria that target primary cancers and associated metastases and locally deliver immunotherapy and adjuvants to stimulate systemic antitumor immunity with minimal side effects.
Funder: National Cancer Institute
Funding type: cooperative_agreement
Funder scheme: U01
Start date: 2020-01-21
End date: 2024-12-31
Investigator: NICHOLAS ARPAIA (lead)
Institutions: Columbia University, COLUMBIA UNIV NEW YORK MORNINGSIDE
Topic: Bacterial Cancer Therapy
Subfield: Biotechnology
Domain: Life Sciences
Funded outputs count: 10
Funder award ID: U01CA247573
OpenAlex ID: G3913917543